To further expand on using the CD68 marker for exploring the myeloid cell compartment, we profiled a small subset of controls (n = 11) and cases (n = 15) from MD Anderson Cancer Centre (n = 8) and the Dutch nation-wide study (n = 18) for tumour-associated macrophages (TAM2), granulocytic myeloid-derived suppressor cells (G-MDSC’s), myeloid-derived suppressor cells (M-MDSC’s), macrophages, granulocytes and monocytes (Supplementary Methods, Supplementary Fig. 3a–c and Supplementary Table 8). This evidence concerns the gene CD68 and neoplasm.